forodesine hydrochloride
Sponsors
BioCryst Pharmaceuticals, Mundipharma K.K.
Conditions
CancerLymphomaRecurrent or Refractory PTCLRecurrent or Refractory T/NK-cell Malignancies
Phase 1
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
CompletedNCT00061880
Start: 2003-02-28End: 2008-01-31Updated: 2013-05-30
BCX-1777 in Treating Patients With Refractory Cancer
CompletedNCT00073944
Start: 2003-04-30Updated: 2013-05-30
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
CompletedNCT00098332
Start: 2004-11-30End: 2011-07-31Updated: 2013-07-10
Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
CompletedNCT00823355
Start: 2009-01-31Target: 24Updated: 2013-09-23
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients
CompletedNCT01776411
Start: 2013-01-31End: 2017-04-26Target: 49Updated: 2017-05-11